Jansitin Duo (Metformin Hydrochloride, Sitagliptin)

Jansitin Duo combines metformin and sitagliptin to address hyperglycemia in type 2 diabetes.

• Type 2 diabetes mellitus: improves overall glycemic control when added to diet and exercise.
• Inadequate control on metformin monotherapy: provides additional glucose‑lowering effect.
• Adjunct to other antidiabetic agents: enhances efficacy of combination therapy in adults.

• Metformin reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, thereby lowering fasting glucose levels. Sitagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which prolongs the activity of endogenous incretin hormones (GLP‑1 and GIP). The elevated incretins stimulate glucose‑dependent insulin secretion and suppress glucagon release, complementing metformin’s actions to achieve better overall blood‑sugar regulation. The combined effect results in reduced post‑prandial glucose excursions and improved HbA1c levels over time.

Like all antidiabetic medicines, Jansitin Duo may be associated with adverse reactions that vary in frequency and severity.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
• Headache: mild to moderate intensity.
• Upper respiratory tract infection: symptoms such as sore throat or nasal congestion.
• Fatigue: feeling unusually tired or weak.

Serious or Rare Side Effects

• Lactic acidosis: severe metabolic disturbance requiring immediate medical attention.
• Severe hypoglycemia: especially when combined with insulin or sulfonylureas.
• Pancreatitis: acute abdominal pain with elevated enzymes.
• Allergic reactions: rash, pruritus, or angioedema.

Before prescribing Jansitin Duo, clinicians should evaluate patient-specific factors and follow safety recommendations.

• Renal function: assess creatinine clearance and adjust use in moderate to severe impairment.
• Hepatic disease: avoid in patients with significant liver dysfunction due to lactic acidosis risk.
• Cardiovascular status: monitor for heart failure, as metformin may exacerbate symptoms.
• Concomitant medications: review for drugs that affect renal clearance or increase hypoglycemia risk.
• Pregnancy and lactation: use only if benefits outweigh potential risks, after professional evaluation.
• Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Jansitin Duo can interact with several medicines; understanding the interaction level helps manage safety.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate renal dysfunction, increasing metformin accumulation.
• Strong CYP2C8 inhibitors (e.g., gemfibrozil): can raise sitagliptin plasma concentrations.
• Insulin or sulfonylureas: combined use may cause severe hypoglycemia.

Moderate Interactions (Monitor Closely)

• Diuretics (thiazides): may enhance metformin‑related lactic acidosis risk.
• ACE inhibitors or ARBs: monitor renal function and potassium levels.
• Rifampin: may reduce sitagliptin efficacy by increasing its metabolism.
• Oral corticosteroids: can elevate blood glucose, requiring dose adjustments.